“Global Circulating Tumor Cell Market to reach a market value of 29.42 Billion by 2031 growing at a CAGR of 13.2%”
The Global Circulating Tumor Cell Market size is expected to reach $29.42 billion by 2031, rising at a market growth of 13.2% CAGR during the forecast period.
The growing healthcare infrastructure and increasing cancer cases in India and China drive the circulating tumor cell market. CTCs, critical for non-invasive cancer detection and monitoring, are gaining attention as vital diagnostic tools in oncology. Thus, the Asia Pacific region witnessed 37% revenue share in the market in 2023. This growth is driven by the increasing prevalence of cancer, rising awareness about early cancer diagnosis, and the adoption of advanced diagnostic technologies. The region also benefits from expanding healthcare infrastructure, substantial investments in medical research, and government initiatives to combat cancer. Additionally, a large patient pool and ongoing collaborations between local research institutions and global biotechnology firms contribute to the region’s dominance.
The demand for non-invasive diagnostic methods, particularly liquid biopsies, has risen dramatically in recent years. Traditional biopsy methods, which require tissue samples to be extracted from patients, are invasive, painful, and carry certain risks. In conclusion, the growing demand for non-invasive biopsy techniques drives the market region.
Additionally, personalized medicine tailors’ healthcare treatments to an individual’s unique genetic makeup, allowing for more precise and effective therapies. In oncology, personalized treatments are particularly important, as cancer cells exhibit significant genetic variability across patients. Thus, as healthcare continues to move in this direction, CTC-based diagnostic tools will become an integral part of the precision oncology landscape.
However, the cost of circulating tumor cell (CTC) detection technologies remains one of the key barriers to the widespread adoption of these tools. The technology required to isolate, detect, and analyze CTCs is advanced and expensive, requiring specialized equipment, reagents, and trained personnel. Additionally, many CTC detection methods are still in the early stages of development. In conclusion, the high cost of circulating tumor cell detection technologies impedes growth.
Many clinical trials involving circulating tumor cells were delayed or halted due to pandemic-related restrictions, reducing the demand for CTC-related technologies and equipment. Routine cancer screenings and non-emergency procedures were deprioritized, leading to a decline in the utilization of circulating tumor cell detection methods. Thus, the COVID-19 pandemic had a negative impact on the market.
Based on product, the market is divided into kits & reagents, devices, and blood collection tubes. In 2023, the kits & reagents segment garnered 44% revenue share in the market. These products are vital for isolating, identifying, and analyzing circulating tumor cells (CTCs), which are key cancer detection and monitoring indicators.
On the basis of end user, the market is segmented into research and academic institutes, hospital & clinics, and diagnostic centers. In 2023, the hospital & clinics segment attained 36% revenue share in the market. These facilities rely on circulating tumor cell technologies for early detection, monitoring disease progression, and assessing treatment efficacy.
Based on specimen, the market is categorized into blood, bone marrow, and others. In 2023, the blood segment registered 46% revenue share in the market. Blood is the most utilized specimen for circulating tumor cell (CTC) analysis due to its accessibility, minimal invasiveness, and ability to provide real-time insights into cancer progression.
By technology, the market is divided into CTC detection & enrichment methods, CTC analysis, and CTC direct detection. In 2023, the CTC detection & enrichment methods segment registered 65% revenue share in the market. This segment is pivotal as it represents the initial step in isolating and identifying circulating tumor cells from blood or other specimens.
Based on application, the market is divided into research & clinical and drug & therapy development. In 2023, the drug & therapy development segment procured 33% revenue share in market. This segment underscores the critical role of CTCs in preclinical and clinical trials for oncology drug discovery and development.
Free Valuable Insights: Global Circulating Tumor Cell Market size to reach USD 29.42 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the North America region generated 30% revenue share in the market. The region’s growth is attributed to its advanced healthcare systems, high adoption of innovative diagnostic techniques, and significant investments in cancer research.
Report Attribute | Details |
---|---|
Market size value in 2023 | USD 11.08 Billion |
Market size forecast in 2031 | USD 29.42 Billion |
Base Year | 2023 |
Historical Period | 2020 to 2022 |
Forecast Period | 2024 to 2031 |
Revenue Growth Rate | CAGR of 13.2% from 2024 to 2031 |
Number of Pages | 293 |
Tables | 520 |
Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
Segments covered | Product, End User, Specimen, Technology, Application, Region |
Country scope |
|
Companies Included | Qiagen N.V, Greiner Bio-One International GmbH, Sysmex Corporation, Miltenyi Biotech B.V & Co kg, Bio-Techne Corporation, Ikonisys, Inc., Menarini Silicon Biosystems SpA, LungLife AI Inc., Aviva Systems Biology Corporation, and ScreenCell |
By Product
By End User
By Specimen
By Technology
By Application
By Geography
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.